Latest Advances in Lung Cancer Research

Neoadjuvant chemotherapy before surgery significantly improves survival in stage IIIA NSCLC, reducing death risk by 30% and increasing 5-year survival to 41% from 26%.

Osimertinib after surgery significantly improves survival in early-stage EGFR-mutated NSCLC, reducing cancer recurrence and offering a new standard of care.

Dr. David Carbone at Ohio State advances lung cancer treatment with immunotherapy and targeted therapies, providing compassionate, personalized care and hope to patients.

FDA approves Opdivo for early-stage NSCLC. This immunotherapy can be used before and after surgery, potentially improving outcomes for patients with resectable lung cancer.

New therapies for EGFR-mutant lung cancer boost survival rates. Researchers combat drug resistance and aim for tailored treatments to enhance patient care and quality of life.

Scientists begin first-ever lung cancer vaccine trials in seven countries. The vaccine aims to prevent cancer in high-risk individuals by boosting immune response. Researchers hope it saves lives.

FDA fast-tracks durvalumab, an immunotherapy drug, for small cell lung cancer. Study shows it may extend patient survival. Decision expected by September 2023. Offers hope for patients.

FDA approves osimertinib for advanced EGFR-mutated NSCLC. This targeted therapy extends progression-free survival in patients who’ve undergone chemoradiation, offering new hope for difficult-to-treat lung cancer.

At WCLC, experts highlighted various side effects of lung cancer treatments, emphasizing thyroid, skin, eye, and lung complications. They stressed the importance of early detection and proactive management for better patient outcomes.

Researchers discovered miR-195-5p molecule could slow lung cancer growth by inhibiting CXCL5 gene. Lab tests show promise, offering hope for future treatments against this deadly disease.

Merck halted a lung cancer trial combining vibostolimab with Keytruda due to ineffectiveness and side effects. This setback highlights challenges in developing TIGIT inhibitors for cancer treatment.